Pasithea Therapeutics Corp. (KTTA) stock
KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.51+0.08 (+17.64%)
Close on Nov 18, 2026Market cap $17.07MP/E –Yield –
Pasithea Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Pasithea Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$17.78M. For fiscal 2025 it was -$15.21M. The highest annual figure on record is -$3.17M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.21M | – |
| FY2024 | Dec 31, 2024 | -$13.92M | – |
| FY2023 | Dec 31, 2023 | -$12.81M | – |
| FY2022 | Dec 31, 2022 | -$11.89M | – |
| FY2021 | Dec 31, 2021 | -$3.17M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.71M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.79M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.87M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.06M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.44M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.32M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.24M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.08M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.20M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.19M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.94M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.15M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.74M | – |
| Q3 FY2021 | Sep 30, 2021 | -$548.44K | – |
| Q2 FY2021 | Jun 30, 2021 | -$499.44K | – |
| Q1 FY2021 | Mar 31, 2021 | -$381.85K | – |
See a number that looks wrong?